Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
22.46
-0.14 (-0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
July 18, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 27, 2024
When you look at EXELIXIS INC (NASDAQ:EXEL), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
June 06, 2024
EXELIXIS INC (NASDAQ:EXEL) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
May 01, 2024
Via
Benzinga
Technical Signals Point to a Possible Breakout for EXELIXIS INC.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via
Chartmill
What Analysts Are Saying About Exelixis Stock
April 10, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
May 31, 2024
Via
Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
May 15, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 12, 2024
These stocks are both experts in their respective fields.
Via
The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
May 10, 2024
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
May 08, 2024
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
Via
InvestorPlace
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
May 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
May 01, 2024
EXEL earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
April 30, 2024
EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 30, 2024
From
Exelixis, Inc.
Via
Business Wire
The Top 3 Biotech Stocks to Buy in April 2024
April 27, 2024
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.
Via
InvestorPlace
NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
April 24, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 16, 2024
From
Exelixis, Inc.
Via
Business Wire
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
March 29, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
3 Biotech Stocks to Buy on the Dip: March 2024
March 27, 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Via
InvestorPlace
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
March 23, 2024
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
These stocks are worth buying in most months of the year.
Via
The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
March 06, 2024
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
Via
InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
March 05, 2024
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.